Key Developments: Alexion Pharmaceuticals Inc (ALXN.O)
92.22USD
14 Jun 2013
$-1.19 (-1.27%)
$93.41
$92.95
$93.43
$91.13
940,812
1,459,406
$119.54
$81.82
Latest Key Developments (Source: Significant Developments)
Alexion Pharmaceuticals Inc Reaffirms FY 2013 Guidance-Conference Call
Alexion Pharmaceuticals Inc announced that for fiscal 2013, it expects revenue guidance to be in the range of $1.505 billion to $1.520 billion and Non-GAAP EPS to be in $2.87 to $2.97 range. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $1.518 billion and EPS of $2.92 for fiscal 2013. Full Article
Alexion Pharmaceuticals Inc Raises FY 2013 Guidance
Alexion Pharmaceuticals Inc announced that it is raising its fiscal 2013 revenue guidance from the previous range of $1.490 to $1.505 billion, now to the higher range of $1.505 to $1.520 billion. The upward revision reflects continued global growth of Soliris in PNH and growth from the ongoing launch of Soliris in aHUS. Guidance for fiscal 2013 non-GAAP earnings per share is also being raised, from the previous range of $2.82 to $2.92, now to the higher range of $2.87 to $2.97 per share. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $1.510 billion and EPS of $2.90 for fiscal 2013. Full Article
Alexion Pharmaceuticals Inc Reaffirms FY 2013 Guidance-Conference Call
Alexion Pharmaceuticals Inc announced that for fiscal 2013, it expects revenues to increase by 33% to $1.49 billion to $1.505 billion and non-GAAP EPS increase by 37% over 2012, to $2.82 to $2.92 per share. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report EPS of $2.89 for fiscal 2013. Full Article
Alexion Pharmaceuticals Inc Issues FY 2013 Guidance Above Analysts' Estimates
Alexion Pharmaceuticals Inc announced that for fiscal 2013, it expects worldwide net product sales to be within a range of $1.490 billion to $1.505 billion and non-GAAP earnings per share (EPS) in the range of $2.82 to $2.92. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $1.485 billion and EPS of $2.81 for fiscal 2013. Full Article
Alexion Pharmaceuticals Inc Reaffirms FY 2012 Guidance-Conference Call
Alexion Pharmaceuticals Inc raised fiscal 2012, it expects revenue of $1.120 to $1.130 billion and non-GAAP earnings per share (EPS) to be in the range of $1.99 to $2.04 per share. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenues of $1.129 and EPS of $2.02 for fiscal 2012. Full Article
Alexion Pharmaceuticals Inc Announces $400 Million Share Repurchase Program
Alexion Pharmaceuticals Inc announced that the Company’s Board of Directors has authorized the repurchase of up to $400 million of Alexion common stock. Under the program, purchases may be made from time to time on the open market, or through privately negotiated transactions, block transactions, or other techniques, as determined by the Company’s management and in accordance with prevailing market conditions and the requirements of the Securities and Exchange Commission. Alexion expects to fund all purchases from cash on hand and future cash flows from operations. The Board’s authorization is open-ended and does not establish a timeframe for the purchases. The Company is not obligated to acquire a particular number of shares, and the program may be discontinued at any time at the Company’s discretion. Full Article
Alexion Pharmaceuticals Inc Raises FY 2012 Revenue Guidance; Reaffirms FY 2012 EPS Guidance-Conference Call
Alexion Pharmaceuticals Inc announced that it is raising fiscal 2012 revenue guidance and expects to be between $1.110-$1.1125 billion. The Company raised it from previous range of $1.065-$1.085 billion and non-GAAP earnings per share (EPS) is expected to be in the range of $1.78-$1.88 per. Full Article
Alexion Pharmaceuticals Inc Raises FY 2012 Guidance
Alexion Pharmaceuticals Inc announced that it is raising fiscal 2012 revenue guidance from the previous range of $1.065 to $1.085 billion now to the higher range of $1.110 to $1.125 billion. Guidance for fiscal 2012 non-GAAP earnings per share (EPS) is being raised, from the previous range of $1.65 to $1.75 per share, now to the higher range of $1.78 to $1.88 per share for the year. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report EPS of $1.53 for fiscal 2012. Full Article
Alexion Pharmaceuticals Inc Reaffirms FY 2012 Guidance-Conference Call
Alexion Pharmaceuticals Inc announced that for fiscal 2012, it has revised revenue guidance upwards to $1.065 billion to $1.085 billion. The previous guidance was $1.04 billion to $1.07 billion. Non-GAAP EPS revised upwards to $1.65 to $1.75. The previous guidance was $1.60 to $1.70. Full Article
Alexion Pharmaceuticals Inc Raises FY 2012 Guidance
Alexion Pharmaceuticals Inc announced that it is raising its fiscal 2012 revenue guidance from the previous range of $1.04 to $1.07 billion now to the higher and narrower range of $1.065 to $1.085 billion. The upward revision reflects continued global growth of Soliris in PNH and initial growth in aHUS. With this increased revenue forecast, combined with control of expenses within previously guided ranges, the Company is also raising its guidance for 2012 non-GAAP earnings per share, from the previous range of $1.60 to $1.70 per share now to the higher range of $1.65 to $1.75 per share for the year. All other items of the 2012 financial guidance provided in the Company's press release of February 9, 2012, are being reiterated at this time. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $1.074 billion and EPS of $1.74 for fiscal 2012. Full Article
BRIEF-Alexion Pharmaceuticals shares up 3.1 percent in premarket trade following results
NEW YORK, April 25 - Alexion Pharmaceuticals Inc : * Shares up 3.1 percent in premarket trade following results
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
